Clinical Trials Logo

Shock clinical trials

View clinical trials related to Shock.

Filter by:

NCT ID: NCT01604551 Completed - Septic Shock Clinical Trials

Membrane Shedding During Septic Shock

Start date: May 2003
Phase: N/A
Study type: Observational

Microparticles (MPs) result from plasma cell membrane remodeling and shedding after cell stimulation or apoptosis. MPs are know recognized as a pool of bioactive messengers with emerging role in pathophysiology of immune and cardiovascular diseases. MPs have been characterized during septic shock and may contribute to dissemination of pro-inflammatory and procoagulant mediators. This is a prospective observational study of circulating MPs and blood coagulation in 100 septic shock patients admitted in 3 tertiary hospitals medical ICU at baseline (D1), D2, D3, D4 and D7.

NCT ID: NCT01590511 Completed - Shock Clinical Trials

Echocardiographic Prediction of Fluid Responsiveness After a Mini-fluid Challenge in Non-ventilated Patients With Shock

IVT NonVent
Start date: January 2013
Phase: N/A
Study type: Observational

The main objective of this study is to show that the variation of the subaortic velocity time integral after a mini test by filling 100 cc of normal saline over 1 minute (ΔITV100) is predictive of response to filling (defined as an increase in aortic velocity time integral measured by transthoracic ultrasound over 15% after administration of 500 cc of normal saline over 15 minutes) in non-ventilated shock patients.

NCT ID: NCT01542749 Completed - Heart Failure Clinical Trials

Total Body Albumin Measurement Utilizing a Modification of the BVA 100 Blood Volume Analyzer

Start date: January 2009
Phase: N/A
Study type: Observational

The DAXOR Corporation manufactures and distributes a blood volume analyzer. The analysis is based on the tracer dilution principle utilizing radioiodine labeled human serum albumin. In addition to calculating human blood volume it is hypothesized that measurement of the dilution of the tracer can also yield an accurate measurement of total body albumin.

NCT ID: NCT01528358 Completed - Sepsis Clinical Trials

Tissue Near InfraRed Spectroscopy (NIRS) in Critically Ill Patients

Start date: April 4, 2012
Phase:
Study type: Observational

Hypotheses: 1. In the acute phase of early illness, tissue oxygen saturation and vascular occlusion test (VOT) are important adjuncts in differentiating severe critical illness requiring ICU admission from patients benefiting from less aggressive therapies (non-ICU admission). 2. An early feature of severe sepsis is abnormal microcirculatory vasoreactivity. 3. Microvascular reactivity can be measured by means of vascular occlusion test (VOT) using non-invasive near infrared spectroscopy (NIRS) to measure tissue Oxygen saturation (StO2). 4. Microvascular reactivity is significantly deranged in patients with early severe sepsis and is quantifiably different from non-septic critically ill patients. 5. Other measures of microcirculatory perfusion ie. sublingual orthogonal polarization spectral (OPS) video microscopy, are abnormal and will directionally correlate with VOT and StO2 in severe sepsis 6. In severely septic patients response to therapy can be assessed by VOT and StO2 monitoring and will correlate with prognosis. 7. A management protocol incorporating VOT and StO2 monitoring in addition to conventional hemodynamic and biochemical parameters as a guide to therapy will result in improved outcomes in severely septic patients. This project will investigate the use of a non-invasive near infrared light (NIR) device in conjunction with brief arm compression to measure the microcirculation in critically ill patients. It is know that in patients with overwhelming infections, their blood vessels do not respond normally and the NIR device can help measure how abnormal their blood vessels are. This type of testing is non-invasive and can be performed repeatedly without harm to the patient and may provide an earlier way to determine whether they have overwhelming sepsis and also may help to optimize the treatments they receive and better tailor their treatments to the degree of blood vessel abnormalities that are found. If our hypotheses are correct, this simple non-invasive test could provide a very rapid means of assessing patients that could be done more safely and quickly than some of the current methods. This would have an important effect to enhance patient safety and improve outcomes in such critically ill patients.

NCT ID: NCT01526382 Completed - Septic Shock Clinical Trials

Use of PiCCO System in Critically Ill Patients With Septic Shock and Acute Respiratory Distress Syndrome

PiCCO
Start date: January 2012
Phase: Phase 1/Phase 2
Study type: Interventional

PiCCO has been widely used in critical care settings for several decades. Together with pulmonary artery catheter, it is regarded as the important tool for guiding fluid management in patients with shock or acute respiratory distress syndrome. However, its effects on patients' outcome remain untested. The investigators study is a pilot study that is designed to test whether the use of PiCCO will improve patients' outcome, as compared to those without PiCCO monitoring.

NCT ID: NCT01485315 Completed - Septic Shock Clinical Trials

Transfusion-requirements in Septic Shock Trial

TRISS
Start date: November 2011
Phase: Phase 3
Study type: Interventional

Patients with blood poisoning - sepsis - often receive blood transfusions in the intensive care unit. The evidence that blood transfusion leads to improved outcome is limited and the blood may be harmful to some of these patients. To bridge the gap between clinical practice and evidence, a large randomised clinical trial is needed to document the efficacy and safety of RBC transfusion in these very sick patients

NCT ID: NCT01473498 Completed - Acute Kidney Injury Clinical Trials

Personalized Mean Arterial Pressure Management on Renal Function During Septic Shock

DORESEP
Start date: January 2013
Phase: N/A
Study type: Interventional

Sepsis is the most severe complication of infections. Sepsis-associated Acute kidney injury (AKI) is commonly encountered in critically ill patients and independently predicts poor outcome. Unfortunately, no drug or management strategy was able to reduce incidence of AKI. To adapt the level of mean arterial pressure according to local renal hemodynamic evaluated by renal Doppler could lead to a better renal perfusion, and then less AKI.

NCT ID: NCT01448109 Completed - Septic Shock Clinical Trials

ADjunctive coRticosteroid trEatment iN criticAlly ilL Patients With Septic Shock

ADRENAL
Start date: June 13, 2012
Phase: Phase 4
Study type: Interventional

The purpose of this study is to find out whether adult patients admitted to the Intensive Care Unit with septic shock who are given hydrocortisone compared to placebo (a dummy solution), will have an improved rate of survival 90 days later. Septic shock is the result of an infection, which triggers a complex response by the body (the inflammatory response) that causes a decrease in blood pressure and subsequently one or more organ systems to fail when blood supply to these organs is reduced. This may result in poor recovery and death. About a quarter of the people who suffer septic shock that is not rapidly reversed, will die. When patients are admitted to Intensive Care with sepsis and/or septic shock they receive a number of therapies. These include fluids given through a drip, antibiotics, drugs to boost your blood pressure and other organ systems. In addition to these therapies, steroids (hydrocortisone) are sometimes administered. Whether steroids are useful or not in the treatment of severe infections has been studied for more than 50 years. Previous research has suggested that the use of low dose steroid may have shortterm benefits in improving the circulation. However, there is no agreement amongst doctors around the world about whether treatment with or without low dose steroids improves the overall recovery and survival in patients with septic shock. This study would allow doctors to make informed decisions about whether the addition of low dose steroid therapy is better for patients with septic shock in intensive care. The study will include 3800 intensive care patients who have septic shock. Each enrolled patient will be randomised to receive either Hydrocortisone 200mg or placebo daily for 7 days as a continuous intravenous infusion while in intensive care. The patient will be followed for 90 days. If the patient is discharged prior to 90 days a telephone call will be made for the followup information. At six months the patient will be contacted again for completion of a quality of life questionnaire.

NCT ID: NCT01447875 Completed - Sepsis Clinical Trials

The Effects of Sedative on the Fluid Responsiveness in Critically Ill Patients

Start date: May 2011
Phase: Phase 1
Study type: Interventional

Hypotension and bradycardia are often observed following induction of dexmedetomidine or propofol sedation.Cardiac preload decrease by sedative agents was often considered as one of main causes for this hypotension.The investigators hypothesized that hypotension after induction of sedation is caused by decrease of preload by sedative agents,and passive leg raising (PLR)test could predict this event.Dexmedetomidine or propofol infusion in patients with circulatory failure decrease cardiac preload and enhance preload-dependency and fluid responsiveness.

NCT ID: NCT01443494 Completed - Septic Shock Clinical Trials

High MAP in Septic Shock With Hypertension

Start date: June 2011
Phase: Phase 4
Study type: Interventional

We hypothesized that the increase in MAP from 65 mmHg to patients' usual level improved sublingual microcirculation.